-
Mashup Score: 9
Introduction Salvage stereotactic body radiation therapy (SBRT) for localized prostate cancer recurrence following radiation therapy remains controversial. We performed a systematic review to assess…
Source: onlinelibrary.wiley.comCategories: General Medicine News, Oncologists2Tweet
-
Mashup Score: 3PROstate Multicentre External beam radioTHErapy Using a Stereotactic boost: the PROMETHEUS study protocol - BMC Cancer - 3 month(s) ago
Background High Dose Rate Brachytherapy (HDRB) boost is a well-established treatment for prostate cancer (PC). We describe the PROstate Multicentre External beam radioTHErapy Using Stereotactic boost (PROMETHEUS) study. Non-surgical stereotactic techniques are used to deliver similar doses to HDRB boost regimens with a dose escalation sub-study. Methods Eligible patients have intermediate or high risk PC. PROMETHEUS explores the safety, efficacy and feasibility of multiple Australian centres cooperating in the delivery of Prostate Stereotactic Body Radiotherapy (SBRT) technology. A SBRT boost component Target Dose (TD) of 19Gy in two fractions is to be delivered, followed by a subsequent EBRT component of 46Gy in 23 fractions. Once accrual triggers have been met, SBRT doses can be escalated in 1 Gy increments to a maximum of 22Gy in two fractions. Patient safety will also be measured with the rate of both acute and late moderate to severe Gastro-Intestinal (GI) and Genito-Urinary (GU)
Source: bmccancer.biomedcentral.comCategories: General Medicine News, Oncologists2Tweet
-
Mashup Score: 22
Learn how highly focused, intense radiation can stop lung cancer from growing after it has spread to a small number of sites.
Source: www.mskcc.orgCategories: General Medicine News, Onc News and JournalsTweet-
MSK’s @simonpowell213, along w/@CJTsaiMDPhD & team show adding #SBRT to standard treatment keeps oligoprogressive lung cancer under control more than 4 times longer than standard treatment alone. Results from randomized phase 2 trial in @TheLancet. More: https://t.co/dcAhUkAnX8 https://t.co/ziYyJykWve
-
-
Mashup Score: 0ASTRO 2023: Exploring the Potential for SBRT - 7 month(s) ago
Martin King, MD, PhD, offers insights on SBRT’s potential to redefine treatment in prostate and renal cancer.
Source: www.medscape.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 4Stereotactic Arrhythmia Radioablation: a multicenter pre-post intervention safety evaluation of the Implantable Cardioverter-Defibrillator function - 8 month(s) ago
Stereotactic arrhythmia radioablation (STAR) appears to be beneficial in selected patients with therapy-refractory ventricular tachycardia (VT). Howev…
Source: www.sciencedirect.comCategories: Latest Headlines, Oncologists2Tweet
-
Mashup Score: 0
Stereotactic Body Radiation Therapy (SBRT), STOMP trial, metastatic-directed therapy (MDT), ORIOLE study, tyrosine kinase inhibitor (TKI), American Society for Therapeutic Radiation Oncology (ASTRO), SABR-COMET trial.
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0MRI-guided SBRT cuts radiation toxicity in prostate cancer - 9 month(s) ago
“These findings suggest that the technical advantages in precision of radiotherapy delivery afforded by MRI-guided SBRT translate to measurable clinical benefit.”
Source: www.mdedge.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0Stereotactic Body Radiation Therapy (SBRT) for Oligometastatic Genito-Urinary Cancers – A Review of Prospective Studies STOMPing Out Disease - Beyond the Abstract - 10 month(s) ago
Stereotactic Body Radiation Therapy (SBRT), STOMP trial, metastatic-directed therapy (MDT), ORIOLE study, tyrosine kinase inhibitor (TKI), American Society for Therapeutic Radiation Oncology (ASTRO), SABR-COMET trial.
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 42THE ONCOALERT NETWORK - 10 month(s) ago
Welcome to OncoAlert
Source: THE ONCOALERT NETWORKCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @OncoAlert: The @oncoAlert🚨Newsletter OUT TOMORROW June 29th, 2023‼️ REGISTER to get it📨 https://t.co/yzt83gqQkF Discussing: The Exten…
-
RT @OncoAlert: The @oncoAlert🚨Newsletter OUT TOMORROW June 29th, 2023‼️ REGISTER to get it📨 https://t.co/yzt83gqQkF Discussing: The Exten…
-
RT @OncoAlert: The @oncoAlert🚨Newsletter OUT TOMORROW June 29th, 2023‼️ REGISTER to get it📨 https://t.co/yzt83gqQkF Discussing: The Exten…
-
The @oncoAlert🚨Newsletter OUT TOMORROW June 29th, 2023‼️ REGISTER to get it📨 https://t.co/yzt83gqQkF Discussing: The Extend Trial in #ProstateCancer #SBRT in ☢️Lung Cancer🫁 Genomic Landscape in RAS🧬 best, @weoncologists @jrgralow @neerajaiims @ErikaHamilton9… https://t.co/BnCdKX8EKI https://t.co/aGYE2Mb2dG
-
-
Mashup Score: 0
4yPSARR is an encouraging early predictor of outcome in patients with intermediate-risk PCa treated with SBRT. Validation in prospective trials is warranted.
Source: PubMedCategories: Hem/Oncs, Latest HeadlinesTweet
¿Te has convertido en rescatador prostático mediante #SBRT? Entonces te interesan estas revisiones: - Rescate post-RT https://t.co/k3Y1Fxr6Ox - Rescate post-prostatectomía https://t.co/UCsjEoLCZk